$94.74
0.66% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US0234361089
Symbol
AMED

Amedisys, Inc. Stock price

$94.74
+2.91 3.17% 1M
+4.74 5.27% 6M
+3.95 4.35% YTD
-1.39 1.45% 1Y
-31.66 25.05% 3Y
-94.83 50.02% 5Y
+65.49 223.90% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.62 0.66%
ISIN
US0234361089
Symbol
AMED
Sector

Key metrics

Market capitalization $3.11b
Enterprise Value $3.32b
P/E (TTM) P/E ratio 35.06
EV/FCF (TTM) EV/FCF 15.14
EV/Sales (TTM) EV/Sales 1.40
P/S ratio (TTM) P/S ratio 1.31
P/B ratio (TTM) P/B ratio 2.59
Revenue growth (TTM) Revenue growth 5.34%
Revenue (TTM) Revenue $2.37b
EBIT (operating result TTM) EBIT $217.41m
Free Cash Flow (TTM) Free Cash Flow $219.42m
Cash position $284.88m
EPS (TTM) EPS $2.70
P/E forward 18.55
P/S forward 1.27
EV/Sales forward 1.36
Short interest 7.69%
Show more

Is Amedisys, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Amedisys, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Amedisys, Inc. forecast:

1x Buy
10%
8x Hold
80%
1x Sell
10%

Analyst Opinions

10 Analysts have issued a Amedisys, Inc. forecast:

Buy
10%
Hold
80%
Sell
10%

Financial data from Amedisys, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,372 2,372
5% 5%
100%
- Direct Costs 1,757 1,757
15% 15%
74%
614 614
15% 15%
26%
- Selling and Administrative Expenses 370 370
28% 28%
16%
- Research and Development Expense - -
-
-
244 244
16% 16%
10%
- Depreciation and Amortization 27 27
10% 10%
1%
EBIT (Operating Income) EBIT 217 217
17% 17%
9%
Net Profit 90 90
536% 536%
4%

In millions USD.

Don't miss a Thing! We will send you all news about Amedisys, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amedisys, Inc. Stock News

Neutral
GlobeNewsWire
27 days ago
BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025.
Neutral
GlobeNewsWire
3 months ago
BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024.
Neutral
GlobeNewsWire
4 months ago
BATON ROUGE, La., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care services, has recognized 47 employees with the prestigious Spirit of Excellence Awards, one of the company's highest honors.
More Amedisys, Inc. News

Company Profile

Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.

Head office United States
CEO Richard Ashworth
Employees 19,000
Founded 1982
Website www.amedisys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today